NASDAQ:TELA TELA Bio (TELA) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free TELA Stock Alerts $5.30 -0.03 (-0.56%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.29▼$5.5250-Day Range$5.30▼$7.6152-Week Range$4.23▼$11.65Volume79,080 shsAverage Volume95,119 shsMarket Capitalization$129.80 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TELA Bio alerts: Email Address TELA Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside176.7% Upside$14.67 Price TargetShort InterestHealthy2.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.96) to ($1.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector408th out of 947 stocksSurgical & Medical Instruments Industry46th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingTELA Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.67, TELA Bio has a forecasted upside of 176.7% from its current price of $5.30.Amount of Analyst CoverageTELA Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.71% of the outstanding shares of TELA Bio have been sold short.Short Interest Ratio / Days to CoverTELA Bio has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in TELA Bio has recently decreased by 7.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTELA Bio does not currently pay a dividend.Dividend GrowthTELA Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TELA. Previous Next 2.7 News and Social Media Coverage News SentimentTELA Bio has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TELA Bio this week, compared to 1 article on an average week.Search Interest5 people have searched for TELA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added TELA Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TELA Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of TELA Bio is held by insiders.Percentage Held by Institutions91.06% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TELA Bio are expected to grow in the coming year, from ($1.96) to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TELA Bio is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TELA Bio is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTELA Bio has a P/B Ratio of 7.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About TELA Bio Stock (NASDAQ:TELA)TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Read More TELA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TELA Stock News HeadlinesMarch 14, 2024 | americanbankingnews.comTELA Bio (TELA) to Release Quarterly Earnings on ThursdayMarch 7, 2024 | finance.yahoo.comTELA Jul 2024 10.000 callMarch 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …March 7, 2024 | finance.yahoo.comTELA Jul 2024 7.500 putFebruary 29, 2024 | globenewswire.comTELA Bio to Announce Fourth Quarter and Full Year 2023 Financial ResultsFebruary 25, 2024 | msn.comTELA Bio Awards Restricted Stock Units to New Hires in Bid to Attract Top TalentFebruary 23, 2024 | globenewswire.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 17, 2024 | finance.yahoo.comWith 54% institutional ownership, TELA Bio, Inc. (NASDAQ:TELA) is a favorite amongst the big gunsMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.February 3, 2024 | morningstar.comTELA Bio Inc Ordinary SharesJanuary 16, 2024 | seekingalpha.comTELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong BuyJanuary 12, 2024 | finance.yahoo.comTELA Bio, Inc. (TELA) Stock Historical Prices & Data - Yahoo FinanceDecember 27, 2023 | realmoney.thestreet.comTELA Bio shares offer 'attractive upside for 2024,' says Lake StreetDecember 5, 2023 | finance.yahoo.comTELA Bio to Take Part in Connecting the DotsDecember 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), TELA Bio (TELA) and Smith & Nephew Snats (SNN)November 16, 2023 | finance.yahoo.comTELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare ConferenceNovember 13, 2023 | msn.comTELA Bio files for $150M mixed shelfNovember 12, 2023 | finance.yahoo.comTELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | morningstar.comTELA Bio Inc Ordinary Shares TELANovember 10, 2023 | finanznachrichten.deTELA Bio, Inc.: TELA Bio Reports Third Quarter 2023 Financial ResultsNovember 10, 2023 | markets.businessinsider.comBuy Rating for TELA Bio: Resilience and Growth Potential despite ChallengesNovember 10, 2023 | msn.comTELA Bio GAAP EPS of -$0.45 misses by $0.29, revenue of $15.1M misses by $1.1MOctober 26, 2023 | finance.yahoo.comTELA Bio to Announce Third Quarter 2023 Financial ResultsSeptember 21, 2023 | finance.yahoo.comOpaleye Management Inc. Reduces Stake in Harrow Health Inc.September 18, 2023 | finance.yahoo.comTELA Bio to Participate in the Gilmartin Group Emerging Growth Company ShowcaseAugust 18, 2023 | bizjournals.comLab Notes: Tela Bio launches new product; Amicus gets approval for its Pompe disease treatment in UKAugust 17, 2023 | msn.comTELA Bio rolls out new OviTex resorbable for implantationSee More Headlines Receive TELA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/19/2024Next Earnings (Confirmed)3/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TELA CUSIPN/A CIK1561921 Webwww.telabio.com Phone484-320-2930FaxN/AEmployees173Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$15.00 Low Stock Price Target$14.00 Potential Upside/Downside+176.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,300,000.00 Net Margins-82.43% Pretax Margin-82.43% Return on Equity-198.87% Return on Assets-56.76% Debt Debt-to-Equity Ratio1.32 Current Ratio5.36 Quick Ratio4.43 Sales & Book Value Annual Sales$41.42 million Price / Sales3.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book7.07Miscellaneous Outstanding Shares24,490,000Free Float23,093,000Market Cap$129.80 million OptionableOptionable Beta0.97 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Antony Koblish (Age 58)Co-founder, President, CEO & Director Comp: $967.67kMr. Roberto E. Cuca J.D. (Age 56)CFO & COO Comp: $643.37kMr. Paul TalmoChief Technology OfficerMs. Megan Smeykal (Age 48)VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Mr. D. Taylor OcasioGeneral Counsel & Corporate SecretaryMs. Jennifer Lou Armstrong (Age 54)Senior Vice President of Human Resources Mr. Gregory A. FirestoneChief Business OfficerMr. Michael LeonardSenior Vice President of Technical OperationsMr. Peter C. Murphy (Age 51)Chief Commercial Officer Comp: $542.34kLouisa SmithInvestor Relations Contact OfficerMore ExecutivesKey CompetitorsAllurion TechnologiesNYSE:ALURNeuroneticsNASDAQ:STIMClearPoint NeuroNASDAQ:CLPTBrainsWayNASDAQ:BWAYKORU Medical SystemsNASDAQ:KRMDView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 22,850 shares on 3/11/2024Ownership: 4.079%Spouting Rock Asset Management LLCSold 2,602 shares on 2/16/2024Ownership: 0.077%Nuveen Asset Management LLCBought 8,220 shares on 2/15/2024Ownership: 0.126%Barclays PLCBought 19,341 shares on 2/15/2024Ownership: 0.091%Citadel Advisors LLCSold 200 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TELA Stock Analysis - Frequently Asked Questions Should I buy or sell TELA Bio stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TELA shares. View TELA analyst ratings or view top-rated stocks. What is TELA Bio's stock price target for 2024? 3 brokers have issued 12-month price objectives for TELA Bio's shares. Their TELA share price targets range from $14.00 to $15.00. On average, they predict the company's stock price to reach $14.67 in the next year. This suggests a possible upside of 176.7% from the stock's current price. View analysts price targets for TELA or view top-rated stocks among Wall Street analysts. How have TELA shares performed in 2024? TELA Bio's stock was trading at $6.62 at the beginning of the year. Since then, TELA stock has decreased by 19.9% and is now trading at $5.30. View the best growth stocks for 2024 here. When is TELA Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our TELA earnings forecast. How can I listen to TELA Bio's earnings call? TELA Bio will be holding an earnings conference call on Thursday, March 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were TELA Bio's earnings last quarter? TELA Bio, Inc. (NASDAQ:TELA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.05. The business had revenue of $7.65 million for the quarter, compared to analysts' expectations of $7.30 million. TELA Bio had a negative trailing twelve-month return on equity of 198.87% and a negative net margin of 82.43%. What other stocks do shareholders of TELA Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU), Intel (INTC), Pfizer (PFE), CrowdStrike (CRWD), Walt Disney (DIS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alteryx (AYX) and Cisco Systems (CSCO). When did TELA Bio IPO? (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are TELA Bio's major shareholders? TELA Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (10.43%), AIGH Capital Management LLC (5.63%), Nantahala Capital Management LLC (4.48%), Vanguard Group Inc. (4.08%), Vanguard Group Inc. (4.08%) and UBS Group AG (2.81%). Insiders that own company stock include Antony Koblish, Ew Healthcare Partners Fund 2-, Ew Healthcare Partners Fund 2,, Gregory A Firestone, Opaleye Management Inc, Orbimed Advisors Llc and Roberto Cuca. View institutional ownership trends. How do I buy shares of TELA Bio? Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TELA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TELA Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.